Related references
Note: Only part of the references are listed.BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
W-J Chng et al.
LEUKEMIA (2011)
New model systems provide insights into Myc-induced transformation
A. R. Wasylishen et al.
ONCOGENE (2011)
Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells
Jin-Jian Lu et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice
Jianxia Guo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma
Ariel Anguiano et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus
Thea Kristin Vatsveen et al.
LEUKEMIA RESEARCH (2009)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
Improved low molecular weight Myc-Max inhibitors
Huabo Wang et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia
Ming-Jer Huang et al.
EXPERIMENTAL HEMATOLOGY (2006)
c-Myc inhibition negatively impacts lymphoma growth
I Gomez-Curet et al.
JOURNAL OF PEDIATRIC SURGERY (2006)
Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation
K Brocke-Heidrich et al.
BLOOD (2004)
Low molecular weight inhibitors of Myc-Max interaction and function
XY Yin et al.
ONCOGENE (2003)
In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp 130/STAT3 pathway
M Chatterjee et al.
BLOOD (2002)
Share Paper
